Table 2.

Association between SOX12 expression and clinicopathologic characteristics

Clinicopathological parameters	Expression of SOX12			χ2	P-value
	Positive (n = 339)	Negative (n = 185)	Total (n = 524)
Age at diagnosis (years)
≤ 35	43	16	59	1.951	0.163
> 35	296	169	465
Pathologic tumor size (cm)
T1	130	98	228	10.462	0.005
T2	183	77	260
T3	26	10	36
Menopausal status
Premenopausal	189	94	283	1.177	0.278
Postmenopausal	150	91	241
Histological grade
1	30	16	46	7.498	0.058
2	153	97	250
3	116	63	179
Unknown	40	9	49
ER
Positive	238	111	349	5.605	0.018
Negative	101	74	175
PR
Positive	245	125	370	1.276	0.259
Negative	94	60	154
HER2
Negative	252	115	367	8.453	0.004
Positive	87	70	157
Lymph node metastasis
Negative	181	128	309	12.344	< 0.001
Positive	158	57	215
TNM
I	52	58	110	22.958	< 0.001
II	206	104	310
III	81	23	104
Ki-67 status
< 20%	98	59	165	4.235	0.120
≥ 20%	241	126	316
P53 status
Positive	227	125	328	2.456	0.293
Negative	75	47	132
Unknown	37	13	21
Molecular subtype
Luminal A	97	44	141	3.899	0.273
Luminal B	160	82	242
HER2 type	52	37	89
TNBC	30	22	52

SOX12, sex-determining region Y-box 12; TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; P-values that reach significance are in bold.